Should You Invest in the iShares Biotechnology ETF (IBB)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on 02/05/2001.
Key Stock Market ETFs Hanging Tough Amidst Volatility
Here we are, another week and another notch on the bull market belt. Last weekend, we were very bullish coming into this past week on Small Caps, Biotechnology and Regional Banks.
iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum
Biotechnology companies experienced an optimistic bullish cycle in 2020-2021, leading to outperformance of the Biotech index. But the cycle of interest rate increases taking place since 2022 has caused several Biotech companies to observe cash flow issues. Advances in AI, machine learning, and generative AI are likely to accelerate drug discovery processes and optimize operations in the biotech and pharma sectors, leading to growth opportunities.
The Biotechnology Sector ETF (IBB) Clears Price Resistance
On June 24, 2024 I wrote a daily called, Biotechnology Sector IBB Breakout Comes To Life: “IBB sits just below the 200-WMA. Plus, he is in the middle of the weekly channel range.
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and, along with rising unemployment, should persuade the Fed to cut rates this year in September.
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotechnology sector, represented by the iShares Biotechnology ETF NASDAQ: IBB, has experienced a year of consolidation. With the ETF up just 0.8%, it has underperformed the broader market, making it one of the worst-performing sectors year-to-date.
$IBB Biotechnology Sector ETF Breakout Comes To Life
Over the weekend as we looked at the entire Economic Modern Family of stock market ETFs, we focused on Big Brother Biotechnology IBB as particularly intriguing. We wrote: “IBB sits just below the 200-WMA.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Should You Invest in the iShares Biotechnology ETF (IBB)?
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on 02/05/2001.
Why the Rest of 2024 Could Be Good for Investing in Biotech Stocks
Innovation has been a hallmark of biotechnology for decades and, despite some of the hardest sledding in many years, 2024 could be a bounce-back year for biotech stocks. The sector has suffered in this cycle.
